Difference between revisions of "Cabozantinib (Cometriq)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
|||
| Line 38: | Line 38: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | + | ||
[[Category:AXL inhibitors]] | [[Category:AXL inhibitors]] | ||
[[Category:FLT3 inhibitors]] | [[Category:FLT3 inhibitors]] | ||
Revision as of 23:06, 28 February 2020
General information
Class/mechanism: Tyrosine kinase inhibitor; inhibits RET, MET/c-Met, VEGFR-1, VEGFR-2, VEGFR-3, KIT, TRKB, FLT-3, AXL, and TIE-2.[1][2][3][4][5][6]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1][4]
Diseases for which it is used
- Hepatocellular carcinoma
- Non-small cell lung cancer
- Prostate cancer
- Renal cell carcinoma
- Medullary thyroid cancer
Patient drug information
- Cabozantinib (Cometriq) package insert pages 20-24[1] (the numbering for the PDF is off, so in some PDF viewers, the patient information is on pages 27-31)
- Cabozantinib (Cabometyx) package insert[4]
- Cabozantinib (Cometriq) patient drug information (Chemocare)[7]
- Cabozantinib (Cometriq) patient drug information (UpToDate)[8]
History of changes in FDA indication
Hepatocellular carcinoma
- 1/14/2019: Approved for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. (new disease entity)
Medullary thyroid cancer
- 11/29/2012: Initial approval (as Cometriq) for treatment of progressive metastatic medullary thyroid cancer (MTC).
Renal cell carcinoma
- 4/25/2016: Approved (as Cabometyx) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy. (new disease entity)
- 12/19/2017: Granted FDA regular approval for treatment of patients with advanced renal cell carcinoma (RCC). (converted to regular approval; no longer requires prior treatment)
Also known as
- Code names: XL184, XL-184
- Brand names: Cometriq is the brand name for cabozantinib's medullary thyroid cancer indication. Cabometyx is the brand name for cabozantinib's renal cell carcinoma indication.
References
- ↑ 1.0 1.1 1.2 Cabozantinib (Cometriq) package insert
- ↑ Cabozantinib (Cometriq) package insert (locally hosted backup)
- ↑ Cometriq manufacturer's website
- ↑ 4.0 4.1 4.2 Cabozantinib (Cabometyx) package insert
- ↑ Cabozantinib (Cabometyx) package insert (locally hosted backup)
- ↑ Cabometyx manufacturer's website
- ↑ Cabozantinib (Cometriq) patient drug information (Chemocare)
- ↑ Cabozantinib (Cometriq) patient drug information (UpToDate)
Categories:
- Drugs
- Oral medications
- AXL inhibitors
- FLT3 inhibitors
- KIT inhibitors
- MET inhibitors
- RET inhibitors
- ROS1 inhibitors
- TEK inhibitors
- TRK inhibitors
- VEGFR inhibitors
- Hepatocellular carcinoma medications
- Non-small cell lung cancer medications
- Prostate cancer medications
- Renal cell carcinoma medications
- Thyroid cancer medications
- FDA approved in 2012